Acetylcholinesterase inhibitors and cognitive stimulation, combined and alone, in treating individuals with mild Alzheimer's disease.
AChEI treatment
Cognitive stimulation
Combined pharmacological and non-pharmacological treatment
Mild Alzheimer’s disease
Journal
Aging clinical and experimental research
ISSN: 1720-8319
Titre abrégé: Aging Clin Exp Res
Pays: Germany
ID NLM: 101132995
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
17
11
2020
accepted:
13
03
2021
pubmed:
26
3
2021
medline:
19
11
2021
entrez:
25
3
2021
Statut:
ppublish
Résumé
Acetylcholinesterase inhibitors (AChEI) and cognitive stimulation (CS) are the standard pharmacological and non-pharmacological treatments for Alzheimer's disease (AD). The aim of this study was to investigate the effects of these treatments, alone or combined, on the neuropsychological profiles of patients with AD. Forty participants were assigned to three groups receiving either only AChEI (n = 14), AChEI + CS (n = 15), or only CS (n = 11). Cognition was evaluated at baseline and after three months. Linear mixed-effects models were used to investigate differences among the treatments in terms of changes in the patients' neuropsychological profiles. Results, although preliminary because of the small sample size, suggest that a general improvement was found in patients who received AChEI + CS and those who received only CS compared with those who received only AChEI. Interestingly, individuals who received only CS showed a significant improvement in immediate memory recall than those who received only AChEI. Furthermore, the group receiving AChEI + CS showed an improvement in delayed recall than the other two groups. The combination of AChEI and CS seems to have the greatest benefit for patients with mild AD. More interestingly, CS alone is more effective than AChEI alone, even in improving memory, considered to be the "lost" cognitive domain in AD.
Sections du résumé
BACKGROUNDS
BACKGROUND
Acetylcholinesterase inhibitors (AChEI) and cognitive stimulation (CS) are the standard pharmacological and non-pharmacological treatments for Alzheimer's disease (AD).
AIMS
OBJECTIVE
The aim of this study was to investigate the effects of these treatments, alone or combined, on the neuropsychological profiles of patients with AD.
METHODS
METHODS
Forty participants were assigned to three groups receiving either only AChEI (n = 14), AChEI + CS (n = 15), or only CS (n = 11). Cognition was evaluated at baseline and after three months. Linear mixed-effects models were used to investigate differences among the treatments in terms of changes in the patients' neuropsychological profiles.
RESULTS
RESULTS
Results, although preliminary because of the small sample size, suggest that a general improvement was found in patients who received AChEI + CS and those who received only CS compared with those who received only AChEI. Interestingly, individuals who received only CS showed a significant improvement in immediate memory recall than those who received only AChEI. Furthermore, the group receiving AChEI + CS showed an improvement in delayed recall than the other two groups.
DISCUSSION
CONCLUSIONS
The combination of AChEI and CS seems to have the greatest benefit for patients with mild AD. More interestingly, CS alone is more effective than AChEI alone, even in improving memory, considered to be the "lost" cognitive domain in AD.
Identifiants
pubmed: 33763839
doi: 10.1007/s40520-021-01837-8
pii: 10.1007/s40520-021-01837-8
pmc: PMC8595160
doi:
Substances chimiques
Cholinesterase Inhibitors
0
Acetylcholinesterase
EC 3.1.1.7
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3039-3045Informations de copyright
© 2021. The Author(s).
Références
Arch Gerontol Geriatr. 2010 Nov-Dec;51(3):245-9
pubmed: 19969381
West J Nurs Res. 2001 Feb;23(1):33-55
pubmed: 11216023
J Alzheimers Dis. 2015;45(2):609-20
pubmed: 25589728
Behav Res Methods. 2017 Aug;49(4):1494-1502
pubmed: 27620283
JAMA. 1994 Apr 6;271(13):985-91
pubmed: 8139083
Br J Psychiatry. 2005 Nov;187:450-5
pubmed: 16260821
Neural Regen Res. 2021 Jan;16(1):58-67
pubmed: 32788448
J Psychiatr Res. 1975 Nov;12(3):189-98
pubmed: 1202204
Int J Geriatr Psychiatry. 2011 Aug;26(8):833-42
pubmed: 20922772
Dement Geriatr Cogn Disord. 2004;18(1):50-4
pubmed: 15084794
JMIR Res Protoc. 2013 Dec 13;2(2):e59
pubmed: 24334248
Neurology. 2000 Jun 27;54(12):2269-76
pubmed: 10881251
J Alzheimers Dis. 2017;56(1):239-248
pubmed: 27911323